Compare Okta, Inc. (OKTA) vs 10X Genomics Inc (TXG) Price & Performance

Okta (OKTA) trades at $167.60, down 1.76% on the day, but remains up 94% year-to-date driven by strong earnings beats and AI-driven demand for cybersecurity. The stock exhibits a bullish technical trend, with moving averages signaling strength and key support at $166. Fundamentally, revenue grew to $2.61 billion in 2025 with a net income margin turning positive at 1.07%, while valuation ratios like P/E of 100.96 reflect high growth expectations. Recent news highlights AI security offerings boosting investor confidence.

Outlook is positive with a consensus price target of $181.61, indicating 8% upside, supported by 75% analyst buy ratings. Opportunities include expanding AI identity governance and enterprise adoption, but risks involve intense competition from CrowdStrike and Microsoft, high valuation multiples, and integration challenges. Net cash flow turned positive in 2025, though debt-to-asset ratio improved to 9.09%.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.